Insufficient angiogenic response to myocardial hypoxia leads to cardiac dysfunction [34], while administration of a VEGF trap reagent delays transition from compensated hypertrophy to decompensated HF in pressure-overloaded hearts [14]. The gene discussed is VEGFA; the disease is hypertrophy.